Michael Charlton to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Michael Charlton has written about Randomized Controlled Trials as Topic.
Connection Strength
0.288
-
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020 Sep; 55(9):811-823.
Score: 0.140
-
Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. Semin Liver Dis. 2021 08; 41(3):225-234.
Score: 0.037
-
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
Score: 0.033
-
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
Score: 0.030
-
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2).
Score: 0.029
-
Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011 Sep 02; 54(3):1063-70.
Score: 0.019